

May 29, 2018

To,  
SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589.

Dear Sirs,

**Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that the Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 29, 2018, approved the draft share purchase agreement to acquire 100% stake in Zorg Laboratories Private Limited (Zorg) for an aggregate consideration of Rs. 5 lacs before adjustments and subject to legal and financial due diligence.

The relevant disclosure as prescribed under Regulation 30 is enclosed as **Annexure 1**.

You are requested to take the same on record.

Thanking You.

Yours faithfully,  
**For Glenmark Pharmaceuticals Ltd.**



**Harish Kuber**  
**Company Secretary & Compliance Officer**

Encl: As above

## Annexure 1

| S.No. | Particulars                                                                                                                                                                                                                                                                   | Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.    | Name of the target entity, details in brief such as size, turnover etc.                                                                                                                                                                                                       | Zorg Laboratories Private Limited having its Registered Office at Vithhal Gajanan Nagar, Gajanan Maharaj Mandir Road, Phursungi, Pune – 412308, Maharashtra, India<br><br>Size- Rs. 1,00,000/- divided into 10,000 equity shares of Rs.10/- each<br><br>Turnover- INR 36.10 Lacs for financial year ended March 31, 2017.                                                                                                                                             |
| 2.    | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length" | The acquisition does not fall within the related party transaction<br>No promoter has any interest in the entity being acquired.                                                                                                                                                                                                                                                                                                                                      |
| 3.    | Industry to which the entity being acquired belongs                                                                                                                                                                                                                           | Trading in Pharmaceuticals.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 4.    | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)                                                                          | Considering the background of the company, it is acquired for business purposes.                                                                                                                                                                                                                                                                                                                                                                                      |
| 5.    | Brief details of any governmental or regulatory approvals required for the acquisition                                                                                                                                                                                        | No Government or regulatory approval required.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 6.    | Indicative time period for completion of the acquisition                                                                                                                                                                                                                      | July 31, 2018, subject to fulfilment of Conditions Precedent in the Share Purchase Agreement.                                                                                                                                                                                                                                                                                                                                                                         |
| 7.    | Nature of consideration - whether cash consideration or share swap and details of the same                                                                                                                                                                                    | Cash consideration                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 8.    | Cost of acquisition or the price at which the shares are acquired                                                                                                                                                                                                             | The aggregate consideration is INR 5.00 Lacs before adjustment due to legal and financial due diligence for acquisition of 10,000 equity shares of Rs.10/- each representing 100% of the paid up equity share capital of Zorg Laboratories Private Limited.                                                                                                                                                                                                           |
| 9.    | Percentage of shareholding / control acquired and / or number of shares acquired                                                                                                                                                                                              | 100% of the paid up equity share capital consisting of 10,000 equity shares of the face value of Rs.10/- each of Zorg Laboratories Private Limited.                                                                                                                                                                                                                                                                                                                   |
| 10.   | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)                        | Zorg Laboratories Private Limited is a company incorporated under the Companies Act 1956 as a private limited company on June 23, 2011.<br>It is engaged in the business of dealing, distributing and marketing of all types of pharmaceutical and chemical products.<br>Turnover of last 3 years<br>2014-15                      INR 19.14 Lacs<br>2015-16                      INR 44.90 Lacs<br>2016-17                      INR 36.10 Lacs<br><br>Country - India |